Evidence map›Paper›PMID 34992402›Full record

ArticleClinical, cosmetic and investigational dermatology2021

Self-Limited Primary Cutaneous Rosai-Dorfman Disease: A Case Report and Literature Review.

Pan Zhang, Fang Liu, Yin Cha, Xiuying Zhang, Mei Cao

Open access · goldAbstract readCase Reports
In one paragraph

Article in Clinical, cosmetic and investigational dermatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Pan ZhangDepartment of Dermatology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, People's Republic of China.
Fang LiuDepartment of Dermatology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, People's Republic of China.ORCID 0000-0003-3456-160X
Yin ChaDepartment of Dermatology, Dali Bai Autonomous Prefecture People's Hospital, Dali, Yunnan Province, People's Republic of China.
Xiuying ZhangDepartment of Dermatology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, People's Republic of China.
Mei CaoDepartment of Dermatology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, People's Republic of China.ORCID 0000-0002-4957-078X
Capital Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rosai-Dorfman disease (RDD), also known as sinus histiocytosis with massive lymphadenopathy (SHML), is a rare, benign, and self-limiting disease. Cutaneous Rosai-Dorfman disease (CRDD) is an exceedingly rare extranodal variant, which is strictly limited to the skin and is easily misdiagnosed. We present the case of a 47-year-old Chinese woman with primary CRDD and a review of relevant literature. The patient had red-yellow papules on her left cheek and chest for more than three months with occasional tenderness. Histopathology showed phagocytic histiocytes in the dermis with the typical presentation of emperipolesis. Immunohistochemistry (IHC) staining showed S100 (+), CD68 (+), and CD1a (-). Based on these findings and the negative systemic presentation, the patient was diagnosed with primary papulonodular-type CRDD, and no treatment regimen was initiated. After three months, the skin lesions partially disappeared, confirming the spontaneous regression of CRDD.

Indexed as

diagnosisgene mutationhistopathologyimmunohistochemistryprimary cutaneous Rosai-Dorfman diseasesinus histiocytosis with massive lymphadenopathytreatment

Identifiers

PMID34992402
PMCPMC8714461
OpenAlexW4200136790

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.